Trials / Completed
CompletedNCT00922311
Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade
Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- The University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Study objective: To investigate the potential anti-proteinuric efficacy of aliskiren, a novel direct renin inhibitor (DRI), in addition to angiotensin receptor blocker (ARB) in immunoglobulin A nephropathy (IgAN) patients at risk of developing progressive renal failure.
Detailed description
This will be an open-label pilot study in which IgAN patients with persistent proteinuria despite maximum dose of ARB treatment will be assigned to receive Aliskiren. There is the optional addition of other anti-hypertensive agents to achieve an optimal target blood pressure of \<130/80 mmHg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren | Titrate from 150 mg daily to 300 mg daily |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2009-06-17
- Last updated
- 2015-07-03
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00922311. Inclusion in this directory is not an endorsement.